HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
Share price
+$55.47 (+82.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
HALOZYME THERAPEUTICS, INC. grew revenue 41.2% to $1.66B over the twelve months to Jun 30, 2026. Operating income fell 12.5% to $597.20M, moving the operating margin from 57.9% to 35.9%. Free cash flow was $806.22M, up 49.1% from a year earlier.
Revenue
$1.66B
+41.2% vs. a year earlier
Operating income
$597.20M
-12.5% vs. a year earlier
Free cash flow
$806.22M
+49.1% vs. a year earlier
EPS, diluted
$3.39
-22.4% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.85B
- P/E ratio
- 36.1
- Price to sales
- 8.92
- Price to book
- 103.45
- Dividend yield
- –
- Free cash flow yield
- 5.43%
Fundamentals
- Revenue
- $1.66B
- Net income
- $413.60M
- EPS, diluted
- $3.39
- Free cash flow
- $806.22M
- Book value per share
- $1.18
- Diluted shares
- 121M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.66B+41.2% YoY
Gross profit
$1.37B+38.2% YoY
Operating income
$597.20M-12.5% YoY
Net income
$413.60M-25.8% YoY
EPS, diluted
$3.39-22.4% YoY
Free cash flow
$806.22M+49.1% YoY
Reported periodTrailing twelve months